Project Grant R01AI186079
Award Date
5/13/25
Completion Date
4/30/30
Dollars Obligated
$667K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
The federal Project Grant award F32AI183625, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to define how the cellular protein SLBP (stem-loop binding protein) promotes the infectivity of human cytomegalovirus (HCMV). The $290,132 award, with a period of performance from November 30, 2024 to June 1, 2026, aims to identify and characterize the novel, pro-viral function of...
This federal Project Grant award, totaling $114,722.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research conducted by the Sloan-Kettering Institute for Cancer Research, a prominent non-profit cancer research organization, to investigate the molecular basis of context-dependent STAT3 function in natural killer (NK) cells. The research aims to determine how...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to improve the understanding of how antibodies can control viral infections through Fc-dependent mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytolysis (CDC). The $318,085 award, effective from December 23, 2024 to...
This R21 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is providing $220,000 to support research at the Fred Hutchinson Cancer Center (also known as the Seattle Cancer Care Alliance) investigating natural killer (NK) cell memory responses to HIV. The key goals of this research project are to identify and characterize HIV-specific NK memory cell clones using a novel...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $131,268 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to George Washington University. The grant supports research to assess the role of the phosphatases PTPN1 and PTPN2 in controlling the activation and expression of cytotoxic proteins in natural killer (NK) cells. The research aims to evaluate the cytolytic activity of NK cells treated with a PTPN1/PTPN2 inhibitor or...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a R21 project grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Brigham & Women's Hospital Inc., a research hospital affiliated with Harvard Medical School. The $425,125 award, spanning from July 2024 to May 2026, will support research to characterize how Epstein-Barr Virus (EBV) transformed B-cells evade natural killer (NK) cell surveillance and resist lysis. The research will utilize a...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $218,068 to support research on the impact of obesity on natural killer (NK) cell function and immune crosstalk with respiratory epithelial cells during influenza virus infection. The primary objectives of this research are to: 1) assess the impact of obesity on NK cell populations and function in response to...
This $193,797 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research by Dr. Jennifer Foltz at The Washington University to investigate mechanisms of natural killer (NK) cell activation and their ability to target and eliminate acute myeloid leukemia (AML). The key objectives are to: 1) Elucidate the transcription factors and epigenetic changes underlying conventional NK (CNK) versus memory-like NK (ML-NK) cell anti-leukemia...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to determine the molecular, cellular, and evolutionary mechanisms by which certain viruses evade or co-opt innate immune peptides called defensins to enhance their infectivity. The $148,568 award, spanning from November 2024 to June 2026, will be conducted at the University of Washington. The research aims...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to generate highly differentiated natural killer (NK) cells that can synergize with broadly neutralizing antibodies to establish viral control in the absence of antiretroviral therapy (ART). The $799,017 award to Emory University seeks to: 1) define the function and distribution of NK cells in tissues from...